Background: The first line treatment for moderate to severe active thyroid associated ophthalmopathy is glucocorticoid pulse therapy, but for patients with contraindications to hormone therapy or hormone resistance, it is urgent to find a suitable treatment plan.
Aims: To find a reliable alternative to hormone pulse therapy for thyroid associated ophthalmopathy by comparing the efficacy with first-line treatment regimens.
Methods: Search PubMed, Ovid, Web of science, Cochrane library, and Clinical Trials.gov for randomized controlled trials on the treatment of thyroid associated ophthalmopathy published as of July 7, 2024. Quality evaluation and Bayesian network analysis were conducted using RevMan 5.3 software, STATA15.0 software, and ADDIS 1.16.8 software.
Results: A total of 666 patients were included in 11 studies and 8 interventions. Network analysis showed that the three interventions of mycophenolate mofetil combined with glucocorticoids, Teprotumumab and 99Tc-MDP were superior to glucocorticoid pulse therapy in improving clinical activity scores and proptosis. The regimen of glucocorticoids combined with statins can improve the quality of life score and diplopia score of patients. Neither methotrexate combined with glucocorticoids nor rituximab alone showed additional advantages when compared with glucocorticoid pulse therapy.
Conclusion: Mycophenolate mofetil combined with glucocorticoid therapy is very beneficial for moderate to severe active thyroid associated ophthalmopathy. Mycophenolate mofetil may be a good choice when patients have contraindications to hormone use or hormone resistance. Teprotumumab is very promising and may be able to avoid patients undergoing orbital decompression surgery. The durability and safety of its long-term efficacy need to be further observed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10792-024-03254-y | DOI Listing |
BMC Endocr Disord
January 2025
Department of Endocrine and Metabolic Diseases, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, No. 185, Juqian Street, Changzhou, 213000, Jiangsu, China.
Background: Microwave ablation is a new, minimally invasive technique for the treatment of thyroid nodules. Hyperthyroidism due to destructive thyroiditis is a known risk of microwave ablation, though it occurs in only a minority of cases. We report a rare case of a patient diagnosed with Graves' disease nearly six months after undergoing microwave ablation of a thyroid nodule.
View Article and Find Full Text PDFSci Rep
January 2025
Health Management Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
This longitudinal study sought to identify distinct body mass index (BMI) trajectories and investigate the impact of these level-independent BMI trajectories on the prevalence of thyroid nodules (TN).This study encompassed a cohort of 1967 participants from a hospital in China. Utilizing latent class growth mixture modeling (LCGMM), four BMI trajectory groups were identified based on the BMI of individuals without TN from 2017 to 2019.
View Article and Find Full Text PDFBMJ Open
January 2025
Vibrant Sciences LLC, Santa Clara, California, USA.
Objective: To evaluate the association between thyroid disease and diabetes markers.
Design: Retrospective cohort study.
Setting: The study was conducted in a diagnostic setting where the primary care providers recommended the patients to test for thyroid and diabetes panels.
Physiol Rep
January 2025
Department of Medicine, John A. Burns School of Medicine, University of Hawaii Mānoa, Honolulu, Hawaii, USA.
Inflammation and a metabolic shift from oxidative metabolism to glycolysis are common in the ischemic heart, the latter partly controlled by pyruvate kinase (muscle, PKM). We previously identified alternative splicing promoting the PKM2 isoform after myocardial infarction (MI). We examined the role of PKM2 physiological upregulation after MI, modeled by ligation of the left anterior descending coronary artery, using global PKM2 knockout (PKM2) mice.
View Article and Find Full Text PDFPhotodiagnosis Photodyn Ther
January 2025
Department of Radiation Oncology, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan, Shandong, China. Electronic address:
Background: Cholangiocarcinoma is a rare but highly fatal malignancy; numerous studies have demonstrated promising outcomes and survival rates associated with adjuvant photodynamic therapy (PDT) in the palliative treatment of cholangiocarcinoma.
Objective: To systematically evaluate the existing meta-analyses on PDT for cholangiocarcinoma, assessing evidence quality and strength while performing updated meta-analyses to refine survival outcomes.
Methods: PubMed, EMBASE, Cochrane Library, and Web of Science were systematically searched up to September 18, 2024, to identify meta-analyses and clinical studies on PDT in patients with cholangiocarcinoma.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!